Anemia in Pregnancy: A Pragmatic Approach

Obstetrical and Gynecological Survey

Volumn 72, Issue 12, 2017, Pages 730-737

  Sun, Dongmei ^a   McLeod, Anne ^b   Gandhi, Shital ^c   Malinowski, Ann Kinga ^d   Shehata, Nadine ^e  

^a WESTERN UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c Obstetric Medicine   (Canada)

^d Division of Maternal Fetal Medicine   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BILIRUBIN; CREATININE; FERRITIN; HAPTOGLOBIN; HEMOGLOBIN; IRON; OXYGEN; PREDNISONE; TRANSFERRIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BIOLOGICAL THERAPY; BLOOD VESSEL OCCLUSION; BODY MASS; CASE REPORT; CESAREAN SECTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; ELEVATED BLOOD PRESSURE; EPIGASTRIC PAIN; FEMALE; FETAL WELL BEING; FETUS DISTRESS; FETUS MORTALITY; GESTATIONAL AGE; HEADACHE; HELLP SYNDROME; HEMATOLOGICAL PARAMETERS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN CELL; HYDRATION; HYPERTENSION; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; LENGTH OF STAY; MACROCYTIC ANEMIA; MATERNAL MORBIDITY; MATERNAL MORTALITY; MATERNAL WELFARE; MEGALOCYTOSIS; NEUTROPHILIA; OXYGEN SUPPLY; PAIN; PALPATION; PATHOGENESIS; PATIENT REFERRAL; PCE/NCE (ERYTHROCYTE); PERINATAL MORBIDITY; PHYSIOLOGICAL PROCESS; PREECLAMPSIA; PREGNANCY; PROTEIN BLOOD LEVEL; PROTEINURIA; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SPHEROCYTOSIS; THALASSEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VIGNETTE; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRENATAL CARE; PROCEDURES;

ANEMIA; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PRENATAL CARE;

EID: 85039762862     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000510     Document Type: Article

References (80)

1. Bencaiova G, Burkhardt T, Breymann C. Anemia-prevalence and risk factors in pregnancy. Eur J Intern Med. 2012;23:529-533.
2. Bora R, Sable C, Wolfson J, et al. Prevalence of anemia in pregnant women and its effect on neonatal outcomes in Northeast India. J Matern Fetal Neonatal Med. 2014;27:887-891.
3. Pavord S, Myers B, Robinson S, et al. UK guidelines on the management of iron deficiency in pregnancy. Br JHaematol. 2012;156:588-600.
4. Blackburn S. Chapter 8 Hematologic and hemostatic systems. In: Maternal, Fetal, & Neonatal Physiology. 4th ed. London, United Kingdom: Elsevier; 2013:216-246.
5. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014;130:1003-1008.
6. Fauce A, Braunwald E, Kasper DL, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, United States:McGraw-Hill Education; 2008.
7. Tunkyi K, Moodley J. Anemia and pregnancy outcomes: a longitudinal study. J Matern Fetal Neonatal Med. 2017;11:1-5.
8. Langlois S, Ford JC, Chitayat D, et al. Carrier screening for thalassemia and hemoglobinopathies in Canada. J Obstet Gynaecol Can. 2008;30:950-971.
9. HorowitzKM, IngardiaCJ, Borgida AF. Anemia in pregnancy. Clin Lab Med. 2013;33:281-291.
10. Mei Z, CogswellME, Looker AC, et al. Assessment of iron status inUS pregnant women from the National Health and Nutrition Examination Survey (NHANES), 1999-2006. Am J Clin Nutr. 2011;93:1312-1320.
11. MilmanN. Iron and pregnancy-a delicate balance. AnnHematol. 2006;85:559-565.
12. Canada H. Prenatal nutrition guidelines for health professionals-iron contributes to a healthy pregnancy. Cited 2009. Available at: http://www.hc-sc.gc.ca/fn-an/pubs/nutrition/iron-fer-eng.php. Accessed October 9, 2017.
13. Corbett RW, Ryan C,Weinrich SP. Pica in pregnancy: does it affect pregnancy outcomes? MCN Am J Matern Child Nurs. 2003;28: 183-189; quiz 90-1.
14. Pena-Rosas JP, De-Regil LM, Dowswell T, et al. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2012;7:CD009997.
15. Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res. 2013;39:504-510.
16. Mishra A, Dave N, Viradiya K. Fatal anaphylactic reaction to iron sucrose in pregnancy. Indian J Pharmacol. 2013;45:93-94.
17. Shi Q, Li J, Yao Q, et al. Intravenous iron sucrose: an alternative for oral iron in pregnancy with iron deficiency anemia. Ann Hematol. 2015;94:523-525.
18. Alwan NA, Cade JE, McArdle HJ, et al. Maternal iron status in early pregnancy and birth outcomes: insights from the Baby's Vascular health and Iron in Pregnancy study. Br J Nutr. 2015;113: 1985-1992.
19. Siu AL. U.S. Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:529-536.
20. George JN, Nester CM. Syndromes of thromboticmicroangiopathy. N Engl J Med. 2014;371:1847-1848.
21. Magee CC, Coggins MP, Foster CS, et al. Case records of the Massachusetts General Hospital. Case 2-2008. A 38-year-old woman with postpartum visual loss, shortness of breath, and renal failure. N Engl J Med. 2008;358:275-289.
22. Sugrue A, Egan A, O'Regan A. A woman with macrocytic anaemia and confusion. BMJ. 2014;349:g4388.
23. Yan M, Malinowski AK, Shehata N. Thrombocytopenic syndromes in pregnancy. Obstet Med. 2016;9:15-20.
24. Magee LA, Abalos E, von Dadelszen P, et al. Howtomanage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011;72:394-401.
25. Magee LA, Pels A, Helewa M, et al; SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary.JObstet Gynaecol Can. 2014;36:416-441.
26. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force onHypertension in Pregnancy.ObstetGynecol. 2013;122:1122-1131.
27. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XIV.
28. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33:196-205.
29. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365:785-799.
30. Martin JN Jr, Rose CH, Briery CM. Understanding andmanaging HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195:914-934.
31. Myers B. Diagnosis and management of maternal thrombocytopenia in pregnancy. Br J Haematol. 2012;158:3-15.
32. Woudstra DM, Chandra S, Hofmeyr GJ, et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev. 2010:CD008148.
33. HaramK, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth. 2009;9:8.
34. Stella CL, Dacus J, Guzman E, et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from4 tertiary hospitals. Am J Obstet Gynecol. 2009;200:381e1-381e6.
35. Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124:211-219.
36. Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015;189:68-72.
37. Sanchez-Luceros A, Farías CE, AmaralMM, et al. Von Willebrand factor-cleaving protease (ADAMTS13) activity in normal nonpregnant women, pregnant and post-delivery women. Thromb Haemost. 2004;92:1320-1326.
38. Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119:5888-5897.
39. Selcuk NY, Odabas AR, Cetinkaya R, et al. Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989-1999). Ren Fail. 2000;22:319-327.
40. Gupta A, Ferguson J, RahmanM, et al. Acute oliguric renal failure inHELLP syndrome: case report and reviewof literature. Ren Fail. 2012;34:653-656.
41. Jiang Y, McIntosh JJ, Reese JA, et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123:1674-1680.
42. Martin JN Jr, Bailey AP, Rehberg JF, et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol. 2008;199:98-104.
43. Alahakoon TI, Zhang W, Trudinger BJ, et al. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro-and anti-angiogenic profiles. J Matern Fetal Neonatal Med. 2014;27:1854-1859.
44. Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13-22.
45. Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956-966.
46. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169:1000-1006.
47. Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J AmSoc Nephrol. 2010;21:859-867.
48. Ardissino G, Wally Ossola M, Baffero GM, et al. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol. 2013;122(2 pt 2):487-489.
49. Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl JMed. 2015;373:1032-1039.
50. Alayed N, Kezouh A, Oddy L, et al. Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births. J Perinat Med. 2014;42:487-492.
51. Costa VM, Viana MB, Aguiar RA. Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes. J Matern Fetal Neonatal Med. 2014;26:1-5.
52. Parrish MR, Morrison JC. Sickle cell crisis and pregnancy. Semin Perinatol. 2013;37:274-279.
53. Larrabee KD, MongaM.Women with sickle cell trait are at increased risk for preeclampsia. Am J Obstet Gynecol. 1997;177:425-428.
54. Daigavane MM, Jena RK, Kar TJ. Perinatal outcome in sickle cell anemia: a prospective study from India. Hemoglobin. 2013;37:507-515.
55. Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125:3316-3325.
56. Howard J,Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381:930-938.
57. Ware RE, Helms RW. SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119:3925-3932.
58. Kjeldsen-Kragh J, Skogen B. Mechanisms and prevention of alloimmunization in pregnancy. Obstet Gynecol Surv. 2013;68: 526-532.
59. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168:291-300.
60. Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015;126:2424-2435.
61. Yawn BP, BuchananGR, Afenyi-Annan AN, et al.Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033-1048.
62. Howard J,Oteng-NtimE. The obstetricmanagement of sickle cell disease. Best Pract Res Clin Obstet Gynaecol. 2012;26:25-36.
63. Chanarin I,McFadyen IR, Kyle R. The physiological macrocytosis of pregnancy. Br J Obstet Gynaecol. 1977;84:504-508.
64. Milman N, Bergholt T, Byg KE, et al. Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. Eur J Haematol. 2007;79:39-46.
65. Mukhopadhyay A, Bhatla N, Kriplani A, et al. Physiological macrocytosis of pregnancy. Trop Doct. 2007;37:42-43.
66. Zarandona JM, Yazer MH. The role of the Coombs test in evaluating hemolysis in adults. CMAJ. 2006;174:305-7.
67. Hoppe B, Stibbe W, Bielefeld A, et al. Increased RBC autoantibody production in pregnancy. Transfusion. 2001;41:1559-1561.
68. Sokol RJ, Hewitt S, Stamps BK. Erythrocyte autoantibodies, autoimmune haemolysis and pregnancy. Vox Sang. 1982;43:169-176.
69. Piatek CI, El-Hemaidi I, Feinstein DI, et al. Management of immune-mediated cytopenias in pregnancy. Autoimmun Rev. 2015;14:806-811.
70. Dhingra S,Wiener JJ, Jackson H.Management of cold agglutinin immune hemolytic anemia in pregnancy. Obstet Gynecol. 2007; 110(2 Pt 2):485-486.
71. Lefkou E, Nelson-Piercy C, Hunt BJ. Evans' syndrome in pregnancy: a systematic literature review and two new cases. Eur J Obstet Gynecol Reprod Biol. 2010;149:10-17.
72. Katsuragi S, Sameshima H, Omine M, et al. Pregnancy-induced hemolytic anemia with a possible immune-related mechanism. Obstet Gynecol. 2008;111(2 pt 2):528-529.
73. Kumar R, Advani AR, Sharan J, et al. Pregnancy induced hemolytic anemia: an unexplained entity. Ann Hematol. 2001;80:623-626.
74. Crowther M, Chan YL, Garbett IK, et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118:4036-4040.
75. Barros MM, Blajchman MA, Bordin JO.Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010;24:195-210.
76. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183:796-804.
77. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385-392.
78. Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes aftermaternal exposure to rituximab. Blood. 2011;117:1499-1506.
79. Raisanen S, Kancherla V, Gissler M, et al. Adverse perinatal outcomes associated with moderate or severe maternal anaemia based on parity in Finland during 2006-10. Paediatr Perinat Epidemiol. 2014;28:372-380.
80. Lumbiganon P, Laopaiboon M, Intarut N, et al; WHO Multicountry Survey on Maternal and Newborn Health Research Network. Indirect causes of severe adverse maternal outcomes: a secondary analysis of the WHO Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121 1 suppl:32-39.